2023 Texas Statutes › Government Code › Title 4 - Executive Branch › Subtitle I - Health and Human Services › Chapter 531 - Health and Human Services Commission › Subchapter B. Powers and Duties › Section 531.0736. Drug Utilization Review Board

Sec. 531.0736.  DRUG UTILIZATION REVIEW BOARD.
Text of subsection effective until April 01, 2025
(a)  In this section, "board" means the Drug Utilization Review Board.
Text of subsection effective until April 01, 2025
(b)  In addition to performing any other duties required by federal law, the board shall:
(1)  develop and submit to the commission recommendations for preferred drug lists adopted by the commission under Section 531.072;
(2)  suggest to the commission restrictions or clinical edits on prescription drugs;
(3)  recommend to the commission educational interventions for Medicaid providers;
(4)  review drug utilization across Medicaid; and
(5)  perform other duties that may be specified by law and otherwise make recommendations to the commission.
Without reference to the amendment of this subsection, this subsection was repealed by Acts 2023, 88th Leg., R.S., Ch. 769 (H.B. 4611), Sec. 3.01(1), eff. April 1, 2025.
(c)  The executive commissioner shall determine the composition of the board, which must:
(1)  comply with applicable federal law, including 42 C.F.R. Section 456.716;
(2)  include three representatives of managed care organizations, all of whom must be physicians or pharmacists;
(3)  include at least 17 physicians and pharmacists who:
(A)  provide services across the entire population of Medicaid recipients and represent different specialties, including at least one of each of the following types of physicians:
(i)  a pediatrician;
(ii)  a primary care physician;
(iii)  an obstetrician and gynecologist;
(iv)  a child and adolescent psychiatrist; and
(v)  an adult psychiatrist; and
(B)  have experience in either developing or practicing under a preferred drug list; and
(4)  include a consumer advocate who represents Medicaid recipients.
Text of subsection effective until April 01, 2025
(c-1)  The executive commissioner by rule shall develop and implement a process by which a person may apply to become a member of the board and shall post the application and information regarding the application process on the commission's Internet website.
(d)  Notwithstanding any other law, members appointed under Subsection (c)(2) may attend quarterly and other regularly scheduled meetings, but may not:
(1)  attend portions of the executive sessions in which confidential drug pricing information is shared; or
(2)  access confidential drug pricing information.
Text of subsection effective until April 01, 2025
(e)  Members of the board serve staggered four-year terms.
Text of subsection effective until April 01, 2025
(f)  The voting members of the board shall elect from among the voting members a presiding officer.  The presiding officer must be a physician.
Text of subsection effective until April 01, 2025
(g)  The board shall hold a public meeting quarterly at the call of the presiding officer and shall permit public comment before voting on any changes in the preferred drug lists, the adoption of or changes to drug use criteria, or the adoption of prior authorization or drug utilization review proposals.  The location of the quarterly public meeting may rotate among different geographic areas across this state, or allow for public input through teleconferencing centers in various geographic areas across this state.  The board shall hold public meetings at other times at the call of the presiding officer.  Minutes of each meeting shall be made available to the public not later than the 10th business day after the date the minutes are approved.  The board may meet in executive session to discuss confidential information as described by Subsection (i).
Text of subsection effective until April 01, 2025
(h)  In developing its recommendations for the preferred drug lists, the board shall consider the clinical efficacy, safety, and cost-effectiveness of and any program benefit associated with a product.
Text of subsection effective until April 01, 2025
(i)  The executive commissioner shall adopt rules governing the operation of the board, including rules governing the procedures used by the board for providing notice of a meeting and rules prohibiting the board from discussing confidential information described by Section 531.071 in a public meeting.  The board shall comply with the rules adopted under this subsection and Subsection (j).
Text of subsection effective until April 01, 2025
(j)  In addition to the rules under Subsection (i), the executive commissioner by rule shall require the board or the board's designee to present a summary of any clinical efficacy and safety information or analyses regarding a drug under consideration for a preferred drug list that is provided to the board by a private entity that has contracted with the commission to provide the information.  The board or the board's designee shall provide the summary in electronic form before the public meeting at which consideration of the drug occurs.  Confidential information described by Section 531.071 must be omitted from the summary.  The summary must be posted on the commission's Internet website.
Text of subsection effective until April 01, 2025
(k)  To the extent feasible, the board shall review all drug classes included in the preferred drug lists adopted under Section 531.072 at least once every 12 months and may recommend inclusions to and exclusions from the lists to ensure that the lists provide for a range of clinically effective, safe, cost-effective, and medically appropriate drug therapies for the diverse segments of the Medicaid population, children receiving health benefits coverage under the child health plan program, and any other affected individuals.
Text of subsection effective until April 01, 2025
(l)  The commission shall provide administrative support and resources as necessary for the board to perform its duties.
Text of subsection effective until April 01, 2025
(m)  Chapter 2110 does not apply to the board.
Text of subsection effective until April 01, 2025
(n)  The commission or the commission's agent shall publicly disclose, immediately after the board's deliberations conclude, each specific drug recommended for or against preferred drug list status for each drug class included in the preferred drug list for the Medicaid vendor drug program.  The disclosure must be posted on the commission's Internet website not later than the 10th business day after the date of conclusion of board deliberations that result in recommendations made to the executive commissioner regarding the placement of drugs on the preferred drug list.  The public disclosure must include:
(1)  the general basis for the recommendation for each drug class; and
(2)  for each recommendation, whether a supplemental rebate agreement or a program benefit agreement was reached under Section 531.070.
Added by Acts 2015, 84th Leg., R.S., Ch. 837 (S.B. 200), Sec. 3.08(b), eff. January 1, 2016.
Added by Acts 2015, 84th Leg., R.S., Ch. 946 (S.B. 277), Sec. 2.08(b), eff. January 1, 2016.
Amended by:
Acts 2023, 88th Leg., R.S., Ch. 739 (H.B. 3286), Sec. 5, eff. September 1, 2023.
Repealed by Acts 2023, 88th Leg., R.S., Ch. 769 (H.B. 4611), Sec. 3.01(1), eff. April 1, 2025.